Tag: Silo Pharma - Page 6 - Psychedelic Alpha

Read more about the article Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Post published:January 26, 2021
Post category:Press Release

Read more about the article Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Post published:January 13, 2021
Post category:Press Release

Read more about the article Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Post published:January 11, 2021
Post category:Press Release

Read more about the article Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Post published:January 6, 2021
Post category:Press Release

Read more about the article Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

Post published:December 15, 2020
Post category:Press Release

Read more about the article Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Post published:December 9, 2020
Post category:Press Release

Read more about the article Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

Post published:December 7, 2020
Post category:Press Release

Read more about the article Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

Post published:December 4, 2020
Post category:Press Release

Read more about the article Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Post published:December 2, 2020
Post category:Press Release

Read more about the article Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

Post published:November 12, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.